Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
Scientists searching for new drugs to fight malaria have identified a number of compounds -- some of which are currently in clinical trials to treat cancer -- that could add to the anti-malarial arsenal.
Sanofi and PATH today announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa.
Resistance to artemisinin, the main drug to treat malaria, is now widespread throughout Southeast Asia, among the Plasmodium falciparum (P. falciparum) parasites that cause the disease and is likely caused by a genetic mutation in the parasites.
A Unanimous Supreme Court: Abortion Rights Lose A Buffer
Yet on Thursday the Supreme Court, in McCullen v. Coakley, struck down that law for violating the First Amendment.
When it comes to the emergence of antimalarial drug resistance, it's not a question of 'if' but 'when'. In order to keep up with the quickly evolving Plasmodium parasite - the cause of malaria - new ways to treat and control the disease must be found.
Depression is the most common mental illness-;affecting a staggering 25 percent of Americans-;but a growing body of research suggests that one of its best cures is cheap and ubiquitous.
Despite unprecedented investment in malaria control in Africa over the past decade, about 57% of the population still live in areas where risk of infection remains moderate to high, according to new research published in The Lancet.
Aggressive multi-resistant infections constitute an increasing health problem all over the world. Bacteria are developing resistance at an alarming pace, so new pharmaceuticals that can combat this threat are in great demand.
'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.
An international team of researchers has discovered a way to identify, at a molecular level, malaria-causing Plasmodium falciparum parasites that are resistant to artemisinin, the key drug for treating this disease.
The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.
The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.
The first malaria elimination programme was in the 1950s and 1960s. Malaria was eliminated from many countries in Asia and the Americas, largely by indoor spraying with insecticide. But the campaign had very little impact in Africa and eventually resources were moved away from malaria control.
For the first time, scientists have developed a novel and rapid way to test whether the most common and lethal form of malaria is resistant to potent artemisinin drugs.
In view of the sharp rise in treatment costs of malaria, the World Health Organization says that there must be a hard diagnosis before the disease is treated.
Exciting progress has been made in the global fight against malaria. The malaria map continues to shrink each year; in the last ten years four countries have been certified malaria-free, and thirty-four additional countries are now working towards malaria elimination targets.
Malaria parasites that develop resistance to the most effective class of anti-malarial drugs may become susceptible to other treatments as a result. The discovery could reveal potential new drug options, which would be essential in the event of resistance to the best anti-malarials.
On World Malaria Day (April 25), the U.N. "warned ... that malaria maintains its impact on less developed countries, mainly in Africa, where millions of people lack needed attention," and in a message marking the day, U.N. Secretary-General Ban Ki-moon "urged political leaders and health authorities of states where malaria is endemic to keep their commitment to achieve universal access to prevention and treatment of malaria".
Testifying before Congress this week, CDC Director Thomas Frieden "said the challenge in the fight against malaria, which in Africa alone kills one child every minute, is staying one step ahead of the malaria parasite" and "cited the need for better public health surveillance, and urged Congress to fund better detection tools".
On World Malaria Day, 25 April, WHO recognizes significant accomplishments in preventing and controlling malaria, including in high-burden countries in sub-Saharan Africa, but highlights the threat of antimalarial drug resistance in south-east Asia's Greater Mekong subregion, where an emergency response is now being launched.